Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cirrhosis, Liver: early-phase trial registry
21 of 35 indexed Cirrhosis, Liver trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #435 of 28,707 conditions by registered trial count.
35 US clinical trials · 21 currently recruiting · #435 of 28,707 conditions by registered trial count
Cirrhosis, Liver: 35 US clinical trials tracked, 21 recruiting.
Cirrhosis, Liver is the subject of 35 registered US clinical trials on ClinicalTrials.gov, 21 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is The Cleveland Clinic, running 3 of these trials.
Enrollment posture brief
Registry condition cirrhosis-liver
OPEN 21 | RECR 60% | LATE 5 | EARLY 9 | RANK #435 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)
Cirrhosis, Liver lists 21 open slots (60% of 35 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cirrhosis, Liver on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cirrhosis, Liver is recruiting above its size-band peers.
21 of 35 indexed trials (60%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cirrhosis, Liver trials is spread across many organizations.
The Cleveland Clinic accounts for 3 of 35 trials (8.6%). 25 distinct sponsors appear on at least one study for this condition label.
-
Typical Cirrhosis, Liver enrolment sits around 74 participants.
Median target enrolment is 74 among the 35 trials that report a genuine target (sentinel values excluded). 19 of those (54.3%) plan for fewer than 100 participants.
-
Cirrhosis, Liver splits between interventional and observational designs.
24 interventional and 11 observational studies make up this index (68.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
35 total, page 1 of 1
Measuring Patient Reported Needs in Outpatient Liver Disease Management
Indiana University
NCT07191886
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
Foundation for the National Institutes of Health
NCT07122700
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT05832229
DELIVER Study in a Population With Clinical Suspicion of Liver Cirrhosis
Owlstone
NCT07035158
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Mercy Medical Center
NCT04588077
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
Massachusetts General Hospital
NCT05998330
Liver Cancer Disparities in American Indian and Alaska Native Persons
University of Washington
NCT05304234
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
University of Wisconsin, Madison
NCT04867954
Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease
University of Pennsylvania
NCT06136221
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
PharmaIN
NCT05490888
EGCG for Hepatocellular Carcinoma Chemoprevention
University of Texas Southwestern Medical Center
NCT06015022
Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant
University of Chicago
NCT06950788
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
Massachusetts General Hospital
NCT06525623
Molecular Mechanism of Exercise in Cirrhosis
The Cleveland Clinic
NCT05982769
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
The Cleveland Clinic
NCT03208868
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
The University of Texas Health Science Center at San Antonio
NCT06526104
HMB Enriched Amino Acids to Reverse Muscle Loss in Cirrhosis
The Cleveland Clinic
NCT05166499
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
University of Chicago
NCT06871111
Transitional Care Program for Fluid Overload in Cirrhosis
Milton S. Hershey Medical Center
NCT06174272
Danazol for Treatment of Cytopenias in Patients With Cirrhosis
University of Southern California
NCT04873102
A Study of SIPLIZUMAB in AILD and LT Patients
Elizabeth C. Verna
NCT06455280
Liver Cirrhosis Network Cohort Study
Northwestern University
NCT05740358
ALTA TIPS: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement
University of Texas Southwestern Medical Center
NCT03973372
Case-Control Study of the Glycotest™ HCC Panel Vs AFP for the Detection of Early-stage Hepatocellular Carcinoma
Glycotest
NCT03878550
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Madrigal Pharmaceuticals
NCT05500222
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Joslin Diabetes Center
NCT04595474
LiveSMART Trial to Prevent Falls in Patients With Cirrhosis - Supplementary Study
University of Michigan
NCT07140120
Liver Cancer Prevention Randomized Control Trial
M.D. Anderson Cancer Center
NCT05196867
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
Indiana University
NCT04383951
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00006164
LiveSMART Trial to Prevent Falls in Patients With Cirrhosis
University of Michigan
NCT05794555
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
Madrigal Pharmaceuticals
NCT04643795
Prophylactic Antibiotics in Admitted Cirrhotics
Beth Israel Deaconess Medical Center
NCT04218695
LiverPAL: A Pilot Study of Inpatient Palliative Care for Patients With Advanced Liver Disease
Massachusetts General Hospital
NCT04953143
TIPS Plus Transvenous Obliteration for Gastric Varices
University of Illinois at Chicago
NCT04044248
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 5 |
| Phase 3 | 3 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Cirrhosis, Liver records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cirrhosis, Liver trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cirrhosis, Liver page
35 registered trials, 21 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 21 Cirrhosis, Liver trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- The Cleveland Clinic sponsors the most Cirrhosis, Liver trials on record, review their full trial history before evaluating a specific study. See The Cleveland Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cirrhosis, Liver condition card totals 35 registered trials; most-linked intervention LiverPal Intervention; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.